Miami, Florida – The International Society for Stem Cell Application (ISSCA) is pleased to announce a new date for practical certification at the highly anticipated 2023 World Congress of Regenerative Medicine in Istanbul, Turkey. Due to the overwhelming demand for clinical experience with real patients, ISSCA has extended the event, providing doctors with an extra day of hands-on training.

The original three-day event, scheduled from November 10 to 12, 2023, includes two days of stimulating conferences and lectures on November 10 and 11, conducted by distinguished physicians from around the world. This covers subjects pertinent to basic science, current advancements, and clinical experiences.

Due to an unprecedented response, the hands-on clinical experience day, November 12, is already at full capacity for the initial package subscribers. However, ISSCA has made the prudent decision to open a new date for training on November 13, 2023. This additional date offers an opportunity for new participants to benefit from valuable hands-on experience while also participating in the two days of conferences on November 10 and 11.

To facilitate a comprehensive understanding of the training and certification programs offered during the World Congress, ISSCA has launched a dedicated website showcasing agendas for various days and different package options. For more information, please visit

What to Expect at the ISSCA World Congress of Regenerative Medicine

The ISSCA World Congress of Regenerative Medicine serves as a global platform for the advancement of cellular therapies, related technologies, and clinical applications. This annual gathering brings together eminent scientists and physicians from over 30 countries for three days of conferences, lectures, and hands-on clinical application workshops.

Key focus areas for this year’s event include:

  • Molecular Biology
  • New treatment models in surgical and cosmetic applications
  • The latest innovations in regenerative Medicine

Furthermore, the conference will explore the legal implications of regenerative medicine practices worldwide.

A Transformative Experience

The ISSCA 2023 World Congress in Istanbul is a must-attend event for all those interested in regenerative medicine. Focused on innovation, collaboration and knowledge sharing, the congress expects to be a transformative experience for scientists, physicians and healthcare professionals from around the world.

For more information about the November 10 to 13 ISSCA World Congress 2023, please visit our official website today.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.

The mission of the International Stem Cell Certification Agency (ISSCA) is to establish itself as a global leader in regenerative medicine certification, education, research, and training.

ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.

About Global Stem Cells Group:

The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.

GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV.

To learn more about Global Stem Cells Group, Inc.’s companies visit our website or call +1 305 560 5331

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Previous Post
ISSCA Announces Partnership with Turkish Stem Cell Society and Endorsement by Leading Turkish Universities for Regenerative Medicine Congress
Next Post
Global Stem Cells Group and ReGen Inaugurate New Franchise Clinic in Tashkent, Uzbekistan

Latest posts